These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 35763348)

  • 61. Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine.
    Freed DC; Tang Q; Tang A; Li F; He X; Huang Z; Meng W; Xia L; Finnefrock AC; Durr E; Espeseth AS; Casimiro DR; Zhang N; Shiver JW; Wang D; An Z; Fu TM
    Proc Natl Acad Sci U S A; 2013 Dec; 110(51):E4997-5005. PubMed ID: 24297878
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector.
    Schleiss MR; Berka U; Watson E; Aistleithner M; Kiefmann B; Mangeat B; Swanson EC; Gillis PA; Hernandez-Alvarado N; Fernández-Alarcón C; Zabeli JC; Pinschewer DD; Lilja AE; Schwendinger M; Guirakhoo F; Monath TP; Orlinger KK
    Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27795301
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Original Antigenic Sin Shapes the Immunological Repertoire Evoked by Human Cytomegalovirus Glycoprotein B/MF59 Vaccine in Seropositive Recipients.
    Baraniak I; Kern F; Holenya P; Griffiths P; Reeves M
    J Infect Dis; 2019 Jun; 220(2):228-232. PubMed ID: 30815685
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pathogenesis of Wild-Type-Like Rhesus Cytomegalovirus Strains following Oral Exposure of Immune-Competent Rhesus Macaques.
    Yue Y; Chang WLW; Li J; Nguyen N; Schmidt KA; Dormitzer PR; Yang X; Barry PA
    J Virol; 2022 Feb; 96(3):e0165321. PubMed ID: 34788083
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Evaluation of virological procedures to detect fetal human cytomegalovirus infection: avidity of IgG antibodies, virus detection in amniotic fluid and maternal serum.
    Ruellan-Eugene G; Barjot P; Campet M; Vabret A; Herlicoviez M; Muller G; Levy G; Guillois B; Freymuth F
    J Med Virol; 1996 Sep; 50(1):9-15. PubMed ID: 8890034
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A high-affinity native human antibody neutralizes human cytomegalovirus infection of diverse cell types.
    Kauvar LM; Liu K; Park M; DeChene N; Stephenson R; Tenorio E; Ellsworth SL; Tabata T; Petitt M; Tsuge M; Fang-Hoover J; Adler SP; Cui X; McVoy MA; Pereira L
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1558-68. PubMed ID: 25534746
    [TBL] [Abstract][Full Text] [Related]  

  • 67. IgA binds to the AD-2 epitope of glycoprotein B and neutralizes human cytomegalovirus.
    Siddiqui S; Hackl S; Ghoddusi H; McIntosh MR; Gomes AC; Ho J; Reeves MB; McLean GR
    Immunology; 2021 Mar; 162(3):314-327. PubMed ID: 33283275
    [TBL] [Abstract][Full Text] [Related]  

  • 68. DNA vaccine prime followed by boost with live attenuated virus significantly improves antigen-specific T cell responses against human cytomegalovirus.
    Gil A; Shen S; Coley S; Gibson L; Diamond DJ; Wang S; Lu S
    Hum Vaccin Immunother; 2013 Oct; 9(10):2120-32. PubMed ID: 24051429
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age.
    Adler SP; Starr SE; Plotkin SA; Hempfling SH; Buis J; Manning ML; Best AM
    J Infect Dis; 1995 Jan; 171(1):26-32. PubMed ID: 7798679
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Repertoire characterization and validation of gB-specific human IgGs directly cloned from humanized mice vaccinated with dendritic cells and protected against HCMV.
    Theobald SJ; Kreer C; Khailaie S; Bonifacius A; Eiz-Vesper B; Figueiredo C; Mach M; Backovic M; Ballmaier M; Koenig J; Olbrich H; Schneider A; Volk V; Danisch S; Gieselmann L; Ercanoglu MS; Messerle M; Kaisenberg CV; Witte T; Klawonn F; Meyer-Hermann M; Klein F; Stripecke R
    PLoS Pathog; 2020 Jul; 16(7):e1008560. PubMed ID: 32667948
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Vaccine strategies against human cytomegalovirus infection.
    Zhong J; Khanna R
    Expert Rev Anti Infect Ther; 2007 Jun; 5(3):449-59. PubMed ID: 17547509
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Horizontal Transmission of Cytomegalovirus in a Rhesus Model Despite High-Level, Vaccine-Elicited Neutralizing Antibody and T-Cell Responses.
    Li J; Wellnitz S; Chi XS; Yue Y; Schmidt KA; Nguyen N; Chen W; Yurgelonis I; Rojas E; Liu Y; Loschko J; Pollozi E; Matsuka YV; Needle E; Vidunas E; Donald RGK; Moran J; Jansen KU; Dormitzer PR; Barry PA; Yang X
    J Infect Dis; 2022 Sep; 226(4):585-594. PubMed ID: 35413121
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Longitudinal Trends of Prevalence of Neutralizing Antibody against Human Cytomegalovirus over the Past 30 Years in Japanese Women.
    Shibamura M; Yamada S; Yoshikawa T; Inagaki T; Nguyen PHA; Fujii H; Harada S; Fukushi S; Oka A; Mizuguchi M; Saijo M
    Jpn J Infect Dis; 2022 Sep; 75(5):496-503. PubMed ID: 35491225
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cytomegalovirus vaccine development.
    Schleiss MR
    Curr Top Microbiol Immunol; 2008; 325():361-82. PubMed ID: 18637516
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Baseline antibody level may help predict the risk of active human cytomegalovirus infection in a HCMV seropositive population.
    Li TD; Li JJ; Huang X; Wang H; Guo XY; Ge SX; Zhang J
    Eur J Clin Microbiol Infect Dis; 2017 May; 36(5):863-868. PubMed ID: 28032284
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A DNA-based vaccine for the prevention of human cytomegalovirus-associated diseases.
    Selinsky C; Luke C; Wloch M; Geall A; Hermanson G; Kaslow D; Evans T
    Hum Vaccin; 2005; 1(1):16-23. PubMed ID: 17038834
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Screening and diagnosis of congenital cytomegalovirus infection: a 5-y study.
    Halwachs-Baumann G; Genser B; Danda M; Engele H; Rosegger H; Fölsch B; Maurer U; Lackner H; Truschnig-Wilders M
    Scand J Infect Dis; 2000; 32(2):137-42. PubMed ID: 10826897
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Immune Prophylaxis and Therapy for Human Cytomegalovirus Infection.
    Struble EB; Murata H; Komatsu T; Scott D
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445434
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Cytomegalovirus-specific, high-avidity IgG with neutralizing activity in maternal circulation enriched in the fetal bloodstream.
    Nozawa N; Fang-Hoover J; Tabata T; Maidji E; Pereira L
    J Clin Virol; 2009 Dec; 46 Suppl 4(Suppl 4):S58-63. PubMed ID: 19854676
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Exploiting viral natural history for vaccine development.
    Barry PA
    Med Microbiol Immunol; 2015 Jun; 204(3):255-62. PubMed ID: 25794555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.